| http://dbpedia.org/ontology/abstract
|
Каплацизумаб — лекарственный препарат, фрагмент моноклонального антитела для лечения приобретённой тромботической тромбоцитопенической пурпуры. Одобрен для применения: ЕС,США (2019).
, كابلاسيزوماب هو جسم مضاد وحيد النسيلة يرتبط بعامل فون ويليبراند.
, El caplacizumab (DCI; nombre comercial Cab … El caplacizumab (DCI; nombre comercial Cablivi) es un anticuerpo bivalente de dominio único (VHH) diseñado para el tratamiento de la púrpura trombocitopénica trombótica. Este fármaco fue desarrollado por . El 30 de agosto de 2018, se aprobó en la Unión Europea para el "tratamiento de adultos que experimentan un episodio de púrpura trombocitopénica trombótica adquirida (PTTa), como coterapia al uso de plasmaféresis e inmunosupresión". En febrero del 2019, la FDA también lo aprobó para el mismo escenario clínico. aprobó para el mismo escenario clínico.
, Caplacizumab (INN; trade name Cablivi) is … Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis. This drug was developed by Ablynx NV. On 30 August 2018, it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression". It is an anti-von Willebrand factor humanized immunoglobulin. It acts by blocking platelet aggregation to reduce organ injury due to ischemia. Results of the phase II TITAN trial have been reported. In February 2019, caplacizumab-yhdp (Cablivi, Ablynx NV) was approved in the United States for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP). The drug is used in combination with plasma exchange and immunosuppressive therapy. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.ders it to be a first-in-class medication.
, Le caplacicizumab est un fragment d'anticorps monoclonal dirigé contre le facteur de von Willebrand et en cours de test contre le purpura thrombotique thrombocytopénique.
|
| http://dbpedia.org/ontology/alternativeName
|
Cablivi
|
| http://dbpedia.org/ontology/casNumber
|
915810-67-2
|
| http://dbpedia.org/ontology/drugbank
|
DB06081
|
| http://dbpedia.org/ontology/fdaUniiCode
|
2R27AB6766
|
| http://dbpedia.org/ontology/kegg
|
D11160
|
| http://dbpedia.org/ontology/medlinePlus
|
a619030
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/caplacizumab +
|
| http://dbpedia.org/ontology/wikiPageID
|
36389502
|
| http://dbpedia.org/ontology/wikiPageLength
|
7816
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1090916341
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Subcutaneous_injection +
, http://dbpedia.org/resource/Ablynx_NV +
, http://dbpedia.org/resource/Intravenous +
, http://dbpedia.org/resource/Single-domain_antibody +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
, http://dbpedia.org/resource/International_Nonproprietary_Name +
, http://dbpedia.org/resource/Category:Sanofi +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Thrombosis +
, http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/First-in-class_medication +
, http://dbpedia.org/resource/Von_Willebrand_factor +
, http://dbpedia.org/resource/Thrombotic_thrombocytopenic_purpura +
|
| http://dbpedia.org/property/atcPrefix
|
B01
|
| http://dbpedia.org/property/atcSuffix
|
AX07
|
| http://dbpedia.org/property/c
|
1213
|
| http://dbpedia.org/property/casNumber
|
915810
|
| http://dbpedia.org/property/chemspiderid
|
none
|
| http://dbpedia.org/property/dailymedid
|
Caplacizumab
|
| http://dbpedia.org/property/drugbank
|
DB06081
|
| http://dbpedia.org/property/h
|
1891
|
| http://dbpedia.org/property/kegg
|
D11160
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalCa
|
Rx-only / Schedule D
|
| http://dbpedia.org/property/legalEu
|
Rx-only
|
| http://dbpedia.org/property/legalUk
|
POM
|
| http://dbpedia.org/property/legalUs
|
Rx-only
|
| http://dbpedia.org/property/mabType
|
sdAb
|
| http://dbpedia.org/property/medlineplus
|
a619030
|
| http://dbpedia.org/property/n
|
357
|
| http://dbpedia.org/property/o
|
380
|
| http://dbpedia.org/property/pregnancyAu
|
B1
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Intravenous +
, http://dbpedia.org/resource/Subcutaneous_injection +
|
| http://dbpedia.org/property/s
|
10
|
| http://dbpedia.org/property/source
|
zu
|
| http://dbpedia.org/property/synonyms
|
ALX-0081, caplacizumab-yhdp
|
| http://dbpedia.org/property/target
|
http://dbpedia.org/resource/Von_Willebrand_factor +
|
| http://dbpedia.org/property/tradename
|
Cablivi
|
| http://dbpedia.org/property/type
|
mab
|
| http://dbpedia.org/property/unii
|
2
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Monoclonals_for_bone%2C_musculoskeletal%2C_circulatory%2C_and_neurologic_systems +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Drugs.com +
, http://dbpedia.org/resource/Template:Monoclonal-antibody-stub +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Cite_web +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Orphan_drugs +
, http://dbpedia.org/resource/Category:Sanofi +
, http://dbpedia.org/resource/Category:Monoclonal_antibodies +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/VHH +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Caplacizumab?oldid=1090916341&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Caplacizumab +
|
| owl:sameAs |
http://ar.dbpedia.org/resource/%D9%83%D8%A7%D8%A8%D9%84%D8%A7%D8%B3%D9%8A%D8%B2%D9%88%D9%85%D8%A7%D8%A8 +
, http://yago-knowledge.org/resource/Caplacizumab +
, http://fr.dbpedia.org/resource/Caplacizumab +
, http://or.dbpedia.org/resource/%E0%AC%95%E0%AC%BE%E0%AC%AA%E0%AD%8D%E0%AC%B2%E0%AC%BE%E0%AC%B8%E0%AC%BF%E0%AC%9C%E0%AD%81%E0%AC%AE%E0%AC%BE%E0%AC%AC +
, http://ru.dbpedia.org/resource/%D0%9A%D0%B0%D0%BF%D0%BB%D0%B0%D1%86%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1 +
, https://global.dbpedia.org/id/4fgPK +
, http://rdf.freebase.com/ns/m.0k8f7gj +
, http://www.wikidata.org/entity/Q5036030 +
, http://dbpedia.org/resource/Caplacizumab +
, http://es.dbpedia.org/resource/Caplacizumab +
|
| rdf:type |
http://dbpedia.org/class/yago/Compound114818238 +
, http://dbpedia.org/class/yago/Chemical114806838 +
, http://dbpedia.org/class/yago/Substance100019613 +
, http://dbpedia.org/class/yago/Thing100002452 +
, http://dbpedia.org/class/yago/Molecule114682133 +
, http://dbpedia.org/class/yago/Unit109465459 +
, http://dbpedia.org/class/yago/Macromolecule114944888 +
, http://dbpedia.org/class/yago/MonoclonalAntibody115029781 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/Protein114728724 +
, http://dbpedia.org/class/yago/OrganicCompound114727670 +
, http://dbpedia.org/class/yago/Material114580897 +
, http://dbpedia.org/class/yago/WikicatMonoclonalAntibodies +
, http://dbpedia.org/class/yago/Relation100031921 +
, http://dbpedia.org/class/yago/Part113809207 +
, http://dbpedia.org/class/yago/Antibody115027189 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/ontology/MonoclonalAntibody +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Abstraction100002137 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
Caplacizumab (INN; trade name Cablivi) is … Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis. This drug was developed by Ablynx NV. On 30 August 2018, it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression".th plasma exchange and immunosuppression".
, El caplacizumab (DCI; nombre comercial Cab … El caplacizumab (DCI; nombre comercial Cablivi) es un anticuerpo bivalente de dominio único (VHH) diseñado para el tratamiento de la púrpura trombocitopénica trombótica. Este fármaco fue desarrollado por . El 30 de agosto de 2018, se aprobó en la Unión Europea para el "tratamiento de adultos que experimentan un episodio de púrpura trombocitopénica trombótica adquirida (PTTa), como coterapia al uso de plasmaféresis e inmunosupresión". En febrero del 2019, la FDA también lo aprobó para el mismo escenario clínico. aprobó para el mismo escenario clínico.
, Каплацизумаб — лекарственный препарат, фрагмент моноклонального антитела для лечения приобретённой тромботической тромбоцитопенической пурпуры. Одобрен для применения: ЕС,США (2019).
, Le caplacicizumab est un fragment d'anticorps monoclonal dirigé contre le facteur de von Willebrand et en cours de test contre le purpura thrombotique thrombocytopénique.
, كابلاسيزوماب هو جسم مضاد وحيد النسيلة يرتبط بعامل فون ويليبراند.
|
| rdfs:label |
Caplacizumab
, Каплацизумаб
, كابلاسيزوماب
|
